RSS Newsfeeds
Main Page RSS
Pharmaceutical News RSS
|
Wednesday, June 29
Emerging Technologies Tuesday Update (06.28.2005)
From the Lab: Biotechnology
Precision tools make for safer genetic therapy and an imaging technique monitors the development of Alzheimer's disease. By Monya Baker
http://www.technologyreview.com/articles/05/07/issue/ftl_bio.asp?trk=nl
AP: Gene Hunters Flock to Amish Country
Amish families get help with inherited diseases -- and geneticists get a real-world 'lab'. By Paul Elias
http://www.technologyreview.com/articles/05/06/ap/ap_062705.asp?trk=nl
Canada to ban bulk drug sales to U.S.
Canada will shortly announce a ban on bulk sales of drugs to the U.S. as a way of reining in Internet pharmacies that sell cheap medicine to
Americans, the Winnipeg Free Press said.
Link to Article
MSNBC.com
Big Pharma Shows Signs Of Weakness
A look at the performance of sector newsmakers for the week of June 20.
Link to Article
Forbes.com
Fighting Crow's Feet and Cancer
Drug companies have found a new way to make money: cosmeceuticals. But regulators are watching.
Link to Article
MSNBC.com
Headline News: Saturday, June 25, 2005
| Category | Professional Journals | | |  | Antibiotic Treatment Not Necessary For Majority Of Children With Conjunctivitis | | | Most children with infective conjunctivitis (pinkeye) do not need treatment with an antibiotic, suggests a study published online today (Wednesday June 22, 2005) by The Lancet. Full Details |
| Category | Pharmaceutical Companies |
| |  | Safety of the association of Alfuzosin 10 mg OD (Xatral® OD/ Uroxatral®) and Tadalafil 20mg (Cialis®) | | | Full Details |
| |  | FDA Approves UCB’s Keppra® for Use in Childhood Epilepsy | | | Brussels (Belgium), June 24, 2005 - UCB announced today that the U.S. Food and Drug Administration (FDA) has approved the company's anti-epilepsy drug Keppra® (levetiracetam) as add-on therapy in the treatment of partial-onset seizures in children four years of age and older with epilepsy. Full Details |
| Category | Bi otech Companies |
| |  | Cambridge Antibody Technology Announces Data From Phase I Clinical Trial of CAT-354 | | | 23 June | Cambridge, UK…Cambridge Antibody Technology (LSE: CAT; NASDAQ: CATG) today announces that preliminary results of a Phase I clinical trial of CAT-354, a human anti-IL13 monoclonal antibody being studied as a potential treatment for severe asthma, showed CAT-354 to be well tolerated with no safety concerns identified. Full Details |
| |  | Cephalon and Alkermes Announce Agreement for the Commercialization of Vivitrex(R) for the Treatment of Alcohol Dependence | | | FRAZER, Pa. and CAMBRIDGE, Mass., June 24 -- Cephalon, Inc. (Nasdaq: CEPH) and Alkermes, Inc. (Nasdaq: ALKS) announced today that they have entered into an agreement to develop and commercialize Vivitrex(R) (naltrexone long-acting injection) in the United States. Full Details |
| Category | Legislations/Regulations |
| |  | FDA Statement on Guidant Corporation’s Worldwide Physician Communications | | | June 24, 2005 -- "The FDA is pleased that Guidant Corporation is communicating important safety information to the public regarding their implantable defibrillators," said Dr. Daniel Schultz, FDA Director of the Center for Devices and Radiological Health. Full Details |
| | FDA Statement on USDA BSE Positive Test Results | | | June 24, 2005 -- "The Food and Drug Administration, along with the USDA, is committed to ensuring the safety of the U.S. human food and animal feed supply from BSE (bovine spongiform encephalopathy). Today we saw that the system worked. Full Details |
| | FDA Notifies Public That Vail Products, Inc. Issues Nationwide Recall of Enclosed Bed Systems | | | June 24, 2005 -- FDA today is notifying consumers that Vail Products, Inc., Toledo, Ohio, is initiating a nationwide recall of approximately 5,000 "enclosed" bed systems. The Vail Products enclosed bed systems have been found to cause patient entrapments, resulting in severe neurological damage or death due to asphyxiation. Full Details |
| Category | Medical Technology |
| |  | FDA Advisory Panel Voted ABIOMED’s ABIOCOR® Submission Did Not Yet Meet HDE Stand ards; Additional Data Is Requested | | | Danvers, Mass., June 23, 2005—ABIOMED, Inc. (NASDAQ: ABMD) announced that after several rounds of voting, the Circulatory System Devices Panel of the FDA today requested additional information on ABIOMED’s AbioCor® total artificial heart. Full Details |
| |  | Boston Scientific Announces Settlement of Department of Justice Investigation of 1998 Recall | | | Natick, MA (June 24, 2005) -- Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a civil settlement agreement with the U.S. Department of Justice regarding the Department's investigation of the 1998 voluntary recall of the NIR ON® Ranger™ with SOX™ stent system -- a product Boston Scientific no longer markets or sells -- and related events. Full Details |
| |  | Lilly Declares Third-Quarter Dividend | | | INDIANAPOLIS, June 24, 2005 -- The Board of Directors of Eli Lilly and Company (NYSE: LLY) today declared a dividend for the third quarter of 2005 of 38 cents a share on outstanding common stock. This is the same dividend as was paid in the first two quarters and maintains the annual dividend for 2005 at $1.52 per share. Full Details |
|
Headline News: Friday, June 24, 2005
| HealthOrbit.ca | Top | | |  | AstraZeneca Presents New Data For Use Of ZOMIG® (Zolmitriptan) Nasal Spray In Adolescents At The American Headache Society Annual Meeting | | | June 23, 2005 - Philadelphia, PA - New clinical trial data presented today at the 47th American Headache Society (AHS) Annual Scientific meeting showed that AstraZeneca’s ZOMIG (zolmitriptan) Nasal Spray 5 mg achieved a 58.1 percent headache response rate in adolescents compared to 43.3 percent with placebo after one hour (p<0.02) – a 14.8 percent difference. Full Details |
| |  | Eon Labs Receives Final Approval for Bupropion HCl, ER 200mg Tablets and Will Begin Shipping Immediately | | | LAKE SUCCESS, N.Y., Jun 23, 2005 -- Eon Labs, Inc. (Nasdaq: ELAB) announced today that it received final approval for Bupropion HCl, ER 200mg tablets, the generic equivalent of Wellbutrin SR(R)* 200mg tablets. The Company will begin shipping immediately. Full Details |
| |  | Consumer Poll: Food Safety Confidence Will Improve With Mandatory National Animal Identification System | | | KENILWORTH, N.J., June 23 -- A recent poll shows that consumers will become even more confident in the safety and security of the nation's meat and poultry supply if a mandatory National Animal Identification System (NAIS) is implemented. Full Details |
| Category | Biotech Companies |
| |  | Gilead Delivers Termination Notice to Ro che for Tamiflu Development and Licensing Agreement | | | FOSTER CITY, Calif. | June 23, 2005--Gilead Sciences, Inc. (Nasdaq:GILD) today announced that it has delivered a notice of termination to F. Hoffmann-La Roche Ltd (Roche) for material breach of the parties' 1996 Development and License Agreement for Tamiflu(R) (oseltamivir phosphate), an antiviral pill for the treatment and prevention of influenza. Full Details |
| Category | Legislations/Regulations |
| | | FDA Approves New Therapy for HIV Patients with Advanced Disease | | | June 23, 2005 -- The Food and Drug Administration (FDA) announced the approval of Aptivus (tipranavir) capsules, an HIV protease inhibitor, to be given with ritonavir for treatment of HIV-1 infected adults. Full Details |
| | FDA Approves BiDil Heart Failure Drug for Black Patients | | | June 23, 2005 -- The Food and Drug Administration (FDA) approved BiDil (bye-DILL), a drug for the treatment of heart failure in self-identified black patients, representing a step toward the promise of personalized medicine. Full Details |
| |  | Current GM foods can bring benefits but safety assessments must continue | | | 23 JUNE 2005 | GENEVA -- New, genetically modified (GM) foods can contribute to enhancing human health and development, the World Health Organization (WHO) concludes in a new report on GM foods, issued today. Full Details |
| |  | Pfizer to Purchase up to $5 Billion of Common Stock | | | NEW YORK, June 23 -- The Board of Directors of Pfizer Inc today authorized a new program to purchase up to $5 billion of the company's common stock. Full Details |
| | Pfizer to Repatriate Additional $8.6 Billion in Foreign Earnings | | | NEW YORK, June 23 -- The board of directors of Pfizer Inc today approved the repatriation, pursuant to the American Jobs Creation Act of 2004, of an additional $8.6 billion in foreign earnings beyond the initial $28.3 billion previously announced by the company. Full Details |
| |  | Wyeth Declares Common Stock Dividend | | | Madison, N.J., June 23, 2005– At a meeting of the Board of Directors of Wyeth (NYSE:WYE), held today, a dividend of twenty-three cents ($.23) per share on the outstanding shares of Common Stock of this Company was declared payable on September 1, 2005, to stockholders of record at the close of business on August 12, 2005. Full Details |
| | Wyeth Declares Preferred Stock Dividend | | | Madison, N.J., June 23, 2005 – At a meeting of the Board of Directors of Wyeth (NYSE:WYE), held today, a dividend of fifty cents ($.50) per share on the outstanding shares of Preferred Stock of this Company was declared payable on October 3, 2005, to stockholders of record at the close of business on September 13, 2005. Full Details |
|
Wyeth and Purdue Announce Restructuring Plans
Following Pfizer’s (New York, NY) lead in April, Wyeth (Madison, NJ) and Purdue Pharma (Stanford, CT) announced restructuring plans that will result in the downsizing of their workforces.
Link to Article
PharmTech ePt: pharmtech.com
Tuesday, June 28
Your Next Job in Pharma
by
Lyle
on Tue 28 Jun 2005 12:03 AM EDT
These are interesting times for life scientists working in the pharmaceutical industry.
Link to Article
TheScientist.com
Thursday, June 23
Drug firms rushing to change cold medicines
Drug companies are reformulating their products to help put them on grocery store shelves while hurting producers of methamphetamine.
Link to Article
Link to Article
Guidant Begins Enrollment in U.S. Drug Eluting Stent Trial
| |  | Guidant Begins Enrollment in U.S. Drug Eluting Stent Trial; Large-Scale Pivotal Trial to Evaluate Safety and Efficacy of Next-Generation XIENCE V Coronary Stent System | | | INDIANAPOLIS | June 22, 2005--Guidant Corporation (NYSE:GDT) today announced that the company has begun enrollment in its SPIRIT III drug eluting stent clinical trial. Full Details |
Healthorbit.ca
|
|